Join to hear about the need for supply chain reinvention, trends impacting Asia-Pacific businesses and digital supply chain services designed to address operational challenges.
EY supply chain webcast
Life sciences M&A optimism resulted in record deal announcements first quarter
High quality generics in pharmaceutical market
EY supports enterprises’ growth as China enters the EPT era
Choose your deal strategy wisely
2018 M&A Firepower Report: Life sciences deals and data
Life sciences deal intentions remain above trend
Looking beyond China to create a global IVD company
MDR and IVDR: reshaping Europe’s medtech industry
Finding sustainability in biotechnology, pharmaceutical and medical technology
Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.
Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.
We cover key issues in these areas:
Connect with us
Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.
Through ensuring the efficacy of domestically produced generic drugs, the reform aims to increase the quality of care and reduce the financial burden for patients.
Following the two-invoice policy roll-out for pharma, one can expect this will pose similar impacts on MedTech stakeholders.